FORM 4

(Print or Type Pecnonces)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person * Touchon Pascal				2. Issuer Name and Ticker or Trading Symbol Atara Biotherapeutics, Inc. [ATRA]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BOULEVARD, SUITE 900				3. Date of Earliest Transaction (Month/Day/Year) 08/16/2022						X Officer (give title below) Other (specify below) President and CEO				
(Street) SOUTH SAN FRANCISCO, CA 94080				4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)		Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)					Following	Form:	Beneficial
				(Month/Day/Year)	Cod	e V	7 Amoun	(A) or (D)	Price	(IIISIT. 3 a	ind 4)		\ /	Ownership (Instr. 4)
Common	Stock		08/16/2022		S(1)	1	14,806		5.035 2)	457,28	7		D	
Reminder: Report on a separate line for each class of secur				rities beneficially o		Pe co the	ersons whentained in the form di	ho respo in this for splays a	rm are currei	not requesting noting valid	OMB con	formation spond unle trol numbe	ss	1474 (9-02)
				(e.g., puts, calls, w						ly Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Year) Execution Da	Year) 4. Transaction Code (Instr. 8) 5. Numl of Deriv Secur Acqu (A) o Dispc of (D (Instr. 4, and		r an (N ive ies ed ed ed s,	Date Exer ad Expirati Month/Day	on Date	Amo Und Secu	itle and bunt of cerlying urities r. 3 and service of Derivative Security (Instr. 5) Securities Beneficially Owned Following Reported Transaction (Instr. 4)		Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficia Ownershi (Instr. 4) D) ect	
				Code V	(A) (ate xercisable	Expiratio Date	n Title	Amount or Number of Shares				

Reporting Owners

	Relationships					
Reporting Owner Name / Address		10% Owner	Officer	Other		
Touchon Pascal C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO, CA 94080	X		President and CEO			

Signatures

/s/ David Tucker, Attorney-in-Fact for Pascal Touchon	08/18/2022

**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations in connection with the vesting of previously granted restricted stock units.
- (2) The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on August 16, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.